483 related articles for article (PubMed ID: 12169712)
1. Medicine. The intangible value of vaccination.
Rappuoli R; Miller HI; Falkow S
Science; 2002 Aug; 297(5583):937-9. PubMed ID: 12169712
[No Abstract] [Full Text] [Related]
2. Win-win interactions between the public and private sectors.
Batson A
Nat Med; 1998 May; 4(5 Suppl):487-91. PubMed ID: 9585192
[No Abstract] [Full Text] [Related]
3. Public health. U.S. vaccine supply falls seriously short.
Cohen J
Science; 2002 Mar; 295(5562):1998-2001. PubMed ID: 11896251
[No Abstract] [Full Text] [Related]
4. TRIPS, pharmaceutical patents, and access to essential medicines: a long way from Seattle to Doha.
't Hoen E
Chic J Int Law; 2002; 3(1):27-46. PubMed ID: 15709298
[No Abstract] [Full Text] [Related]
5. [Vaccination in a developmental perspective].
Sommerfelt H; Godal T
Tidsskr Nor Laegeforen; 2006 Oct; 126(20):2674-7. PubMed ID: 17057768
[No Abstract] [Full Text] [Related]
6. Rx: higher prices.
Kosterlitz J
Natl J (Wash); 1993 Feb; 25(7):396-9. PubMed ID: 10125572
[TBL] [Abstract][Full Text] [Related]
7. The GO License: only part of the solution.
Batson A; Milstien JB
Health Aff (Millwood); 2008; 27(1):140-2. PubMed ID: 18180489
[TBL] [Abstract][Full Text] [Related]
8. Global perspectives on vaccine financing.
Berman S; Giffin RB
Expert Rev Vaccines; 2004 Oct; 3(5):557-62. PubMed ID: 15485335
[TBL] [Abstract][Full Text] [Related]
9. Policy analysis: an essential research tool for the introduction of vaccines in developing countries.
Mahoney R
J Health Popul Nutr; 2004 Sep; 22(3):331-7. PubMed ID: 15609786
[TBL] [Abstract][Full Text] [Related]
10. The impact of globalization on vaccine development and availability.
Milstien JB; Kaddar M; Kieny MP
Health Aff (Millwood); 2006; 25(4):1061-9. PubMed ID: 16835187
[TBL] [Abstract][Full Text] [Related]
11. [Discount for only one drug of the same group leads to impaired health care quality].
Bergström R
Lakartidningen; 2006 Feb 8-14; 103(6):387-8; discussion 388. PubMed ID: 16536044
[No Abstract] [Full Text] [Related]
12. What are today's orphaned vaccines?
Wilde H
Clin Infect Dis; 2001 Sep; 33(5):648-50. PubMed ID: 11486287
[TBL] [Abstract][Full Text] [Related]
13. TRIPS, pharmaceuticals, developing countries, and the Doha "solution".
Sykes AO
Chic J Int Law; 2002; 3(1):47-68. PubMed ID: 15709299
[No Abstract] [Full Text] [Related]
14. The role of emerging manufacturers in access to innovative vaccines of public health importance.
Milstien JB; Kaddar M
Vaccine; 2010 Feb; 28(9):2115-21. PubMed ID: 20044054
[TBL] [Abstract][Full Text] [Related]
15. Industry perspectives: ensuring vaccination of children and adolescents without financial barriers.
Feinberg MB; Gordon L
Pediatrics; 2009 Dec; 124 Suppl 5():S563-4. PubMed ID: 19948589
[No Abstract] [Full Text] [Related]
16. Essential AIDS medications in India.
Thomas J
Issues Med Ethics; 2000; 8(2):62. PubMed ID: 16323350
[No Abstract] [Full Text] [Related]
17. Private sector joins family planning effort.
Front Lines; 1989 Dec; ():6, 13. PubMed ID: 12343476
[TBL] [Abstract][Full Text] [Related]
18. Pharmaceutical research: cost savings through innovation.
Cohen KR; Levy RA
AAPPO J; 1993 Oct; 3(5):28-36. PubMed ID: 10146463
[No Abstract] [Full Text] [Related]
19. Patent necessity: intellectual property dilemmas in the biotech domain and treatment equity for developing countries.
Spectar JM
Houst J Int Law; 2002; 24(2):227-78. PubMed ID: 16189914
[No Abstract] [Full Text] [Related]
20. Plea to restore public funding for vaccine development.
Puliyel JM
Lancet; 2004 Feb; 363(9409):659. PubMed ID: 14987898
[No Abstract] [Full Text] [Related]
[Next] [New Search]
